CytoMed Therapeutics Ltd. (GDTC) News
Filter GDTC News Items
GDTC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GDTC News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest GDTC News From Around the Web
Below are the latest news stories about CYTOMED THERAPEUTICS LTD that investors may wish to consider to help them evaluate GDTC as an investment opportunity.
CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in IndiaThe latest announcement is out from CytoMed Therapeutics Limited ( (GDTC) ). CytoMed Therapeutics has entered a collaboration with SunAct Cancer Institute in India to advance the use of its allogeneic gamma delta T cells in a Phase 2 clinical trial aimed at treating solid cancers. This partnership seeks to explore the therapy’s safety and efficacy, potentially providing an affordable treatment option for cancer patients in India, while contributing to global cancer research data. More about Cyto |
CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in IndiaBoth entities will jointly sponsor the Phase II clinical trial. |
Sector Update: Health Care Stocks Edge Higher Premarket MondayHealth care stocks were higher in Monday's premarket hours, with the Health Care Select Sector SPDR |
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in IndiaSINGAPORE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic off-the-shelf immunotherapies for the treatment of various cancers, today announced that it has entered into a Business & Research Collaboration Agreement (“BRCA”) with Mumbai-based SunAct Cancer Institute Private Limited |
CytoMed Therapeutics Leads 3 US Penny Stocks To ConsiderAs the U.S. equities market begins 2025 on a challenging note, extending its recent slump, investors are keenly observing potential opportunities amid broader market declines. Penny stocks, despite their vintage moniker, continue to attract attention for those interested in smaller or newer companies with potential value. This article explores three penny stocks that stand out for their financial strength and balance sheet resilience, offering intriguing possibilities for investors seeking... |
CytoMed Therapeutics And 2 Other US Penny Stocks To WatchAs the U.S. stock market takes a breather from its record-setting rally, investors are paying close attention to opportunities that may arise in various sectors. Penny stocks, despite their somewhat outdated name, continue to be a focal point for those interested in smaller or newer companies with growth potential. These stocks can offer unique opportunities at lower price points, and when backed by strong financial health and fundamentals, they present an underappreciated chance for growth... |
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological MalignanciesSINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of blood and solid cancers, is pleased to announce that the first patient has been dosed in its first-in-human Phase I dose-escalation clinical trial (NCT0 |
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market CapAs major U.S. indexes recently experienced a downturn, with technology stocks leading the decline and Treasury yields reaching a three-month high, investors are increasingly seeking opportunities beyond the usual large-cap stocks. Penny stocks, while an older term, continue to represent smaller or newer companies that may offer both affordability and growth potential for those willing to explore them. In this article, we examine three penny stocks that stand out for their financial strength... |
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial GrantCompletion of cash acquisition of licenced cord blood bank expanding CytoMed’s strategy to cord blood-derived biologics through its subsidiary, LongevityBank Pte LtdSINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers including bloo |
CytoMed Acquires Cord Blood Assets, Eyes Regenerative MedicineCytoMed Therapeutics Limited (GDTC) has released an update. CytoMed Therapeutics Limited has expanded its biopharmaceutical focus on cell-based therapies by acquiring a Malaysian cord blood banking license and corresponding assets, including cryopreservation equipment and cord blood units. The move, through its subsidiary LongevityBank, aims to leverage the therapeutic potential of cord blood in regenerative medicine and diseases related to aging. The strategic acquisition signals CytoMed’s inte |